量子点标记分子探针成像技术对乳腺癌CC类趋化因子5和基质金属蛋白酶-9的定量检测及临床意义  

Quantitative detection of CC chemokine ligand 5 and matrix metalloproteinase-9 by QDs-based molecular prediction of breast cancer by

作　　者：朱永云[1] 陈创[1] 谢闵 孙金中[1] 赵迎春 孙圣荣[1] 

机构地区：[1]武汉大学人民医院乳腺甲状腺外科 ,430060 [2] 芜湖市第二人民医院病理科 [3] 芜湖市第二人民医院乳腺外科

出　　处：《中华实验外科杂志》2014年第9期2012-2014,共3页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金青年基金资助项目（81201196）

摘　　要：目的 探讨CC类趋化因子5（CCL5）和基质金属蛋白酶（MMP）-9量子点定量信息对预测乳腺癌预后的价值.方法 利用量子点标记分子探针成像技术检测214例浸润性乳腺癌患者CCL5和MMP-9的表达,获得量子点评分（QDS）,分析定量参数与3年预后的关系.结果 淋巴结阴性、阳性组CCL5 QDS为36.952±3.070、74.822±3.582,Lunminal A、Lunminal B、人类表皮生长因子受体（HER）-2阳性、三阴性组CCL5 QDS为39.134±3.709、70.911±4.984、59.260±5.785、61.316±9.212,CCL5表达差异有统计学意义（P＜0.01）;淋巴结阴性、阳性组MMP-9 QDS为18.912±1.356、39.459±2.083,MMP-9表达差异有统计学意义（P＜0.01）;CCL5 QDS与3年无病生存（3-DFS）呈负相关（r=-0.329,P＜0.01）,MMP-9 QDS与3-DFS呈负相关（r=-0.346,P＜0.01）;MMP-9是乳腺癌的独立预后因素[P＜0.01,曲线下面积（AUC） [95％可信区间（CI）：3.489（1.736 ～7.011）].结论 量子点标记分子探针技术能简便准确地获取乳腺癌中CCL5和MMP-9定量信息,提示乳腺癌在CCL5和MMP-9表达上的异质性.Objective To explore the values for BC prediction in combination with CC chemokine ligand 5 （CCL5） and matrix metalloproteinasec （MMP）-9.Methods The quantitative and accurate determination of CCL5 and MMP-9 of 214 invasive BC tissue were acquired by QD-based immunohistochemistry （QD-IHC） and Wuda imaging analysis system.The relationships of quantitative CCL5 and MMP-9 determination with 3-year disease free survival （3-DFS） were investigated.Results CCL5 QDS of lymph node （-） group and lymph node （±） group was 36.952 ± 3.070 and 74.822 ± 3.582.CCL5 QDS of Lunminal A,Lunminal B,human epidermal growth factor receptor （HER-2） over-expression and triplenegative was 39.134 ±3.709,70.911 ±4.984,59.260 ±5.785,61.316 ±9.212.CCL5 QDS was correlated with lymph node metastasis and molecular sub-type （P 〈 0.01）.MMP-9 QDS of lymph node （-） group and lymph node （±） group was 18.912 ± 1.356,39.459 ±2.083.MMP-9 QDS was correlated with lymph node metastasis （P 〈 0.01）.There was a negative relationship between the expression of CCL5 （r =-0.329,P 〈 0.01） and MMP-9 （r =-0.346,P 〈 0.01） with 3-DFS.On multivariate analysis MMP-9 was indeed an independent predictor of 3-DFS （P 〈 0.01,area under curve （AUC） [95% confidence interval （CI）：3.489 （1.736-7.011）].Conclusion QD-IHC nanotechnology can assess CCL5 and MMP-9 expression in BC accurately and quantitatively,reveal BC heterogeneity.

关 键 词：乳腺癌 量子点标记分子探针 趋化因子5 基质金属蛋白酶-9 

分 类 号：R737.9[医药卫生—肿瘤]